Abstract:Background: The discovery of anticancer drug combinations is a crucial work of anticancer treatment. In recent years, pre-screening drug combinations with synergistic effects in a large-scale search space adopting computational methods, especially deep learning methods, is increasingly popular with researchers. Although achievements have been made to predict anticancer synergistic drug combinations based on deep learning, the application of multi-task learning in this field is relatively rare. The successful practice of multi-task learning in various fields shows that it can effectively learn multiple tasks jointly and improve the performance of all the tasks. Methods: In this paper, we propose MTLSynergy which is based on multi-task learning and deep neural networks to predict synergistic anticancer drug combinations. It simultaneously learns two crucial prediction tasks in anticancer treatment, which are synergy prediction of drug combinations and sensitivity prediction of monotherapy. And MTLSynergy integrates the classification and regression of prediction tasks into the same model. Moreover, autoencoders are employed to reduce the dimensions of input features. Results: Compared with the previous methods listed in this paper, MTLSynergy achieves the lowest mean square error of 216.47 and the highest Pearson correlation coefficient of 0.76 on the drug synergy prediction task. On the corresponding classification task, the area under the receiver operator characteristics curve and the area under the precision-recall curve are 0.90 and 0.62, respectively, which are equivalent to the comparison methods. Through the ablation study, we verify that multi-task learning and autoencoder both have a positive effect on prediction performance. In addition, the prediction results of MTLSynergy in many cases are also consistent with previous studies. Conclusion: Our study suggests that multi-task learning is significantly beneficial for both drug synergy prediction and monotherapy sensitivity prediction when combining these two tasks into one model. The ability of MTLSynergy to discover new anticancer synergistic drug combinations noteworthily outperforms other state-of-the-art methods. MTLSynergy promises to be a powerful tool to pre-screen anticancer synergistic drug combinations.

Improving Drug Sensitivity Prediction and Inference by Multitask Learning

Multi-task deep latent spaces for cancer survival and drug sensitivity prediction

Prediction of drug sensitivity based on multi-omics data using deep learning and similarity network fusion approaches

Anti-cancer Drug Synergy Prediction in Understudied Tissues using Transfer Learning

Multi-task deep latent spaces for cancer survival and treatment response prediction

Multitask CapsNet: an Imbalanced Data Deep Learning Method for Predicting Toxicants

Predicting anticancer synergistic drug combinations based on multi-task learning

Dual-Layer Strengthened Collaborative Topic Regression Modeling for Predicting Drug Sensitivity

Exploiting common patterns in diverse cancer types via multi-task learning

Improving anti-cancer drug response prediction using multi-task learning on graph convolutional networks

Predicting Anticancer Drug Responses Using A Dual-Layer Integrated Cell Line-Drug Network Model

Massively Multitask Networks for Drug Discovery

Model ensembling as a tool to form interpretable multi-omic predictors of cancer pharmacosensitivity

Network-based Multi-Task Learning Models for Biomarker Selection and Cancer Outcome Prediction.

Prediction of Cancer Drug Effectiveness Based on Multi-Fusion Deep Learning Model

[Prediction of cancer drug sensitivity based on genomic feature distribution alignment and drug structure information]

ResisenseNet hybrid neural network model for predicting drug sensitivity and repurposing in breast Cancer

A comprehensive benchmarking of machine learning algorithms and dimensionality reduction methods for drug sensitivity prediction

The prediction of drug sensitivity by multi-omics fusion reveals the heterogeneity of drug response in pan-cancer

An Ensemble Learning Approach for Cancer Drug Prediction

An Improved Anticancer Drug-Response Prediction Based on an Ensemble Method Integrating Matrix Completion and Ridge Regression